ERBB2 and breast carcinoma: With the effort of China’s health reform,27 the number of cancer drug approvals has increased sharply since 2017, reaching levels similar to those in the US and the European Union.28 Second, in July 2017, trastuzumab was first listed in China’s reimbursement drug lists for ERBB2-positive breast cancer.